Patent EA-002158-B1 (EA)
Title: Indane or dihydroindole derivatives
Inventor: PERREGAARD JENS KRISTIAN
IPC: G11C7/10
Filed: 1997-12-19
Abstract: 1. A substituted indane or dihydroindole compound of Formula I   wherein A is a group of Formula   Y is a hydrocarbon group completing an indane ring, a group NR<1> completing a dihydroindole ring, or a group N completing a dihydroindole ring linked via the 1-position; W is a bond, and n+m is 1, 2, 3, 4, 5, or 6; W is CO, SO, or SO2, n is 2, 3, 4, or 5 and m is 0, 1, 2, or 3, provided that n+m is not more than 6; or W is O, S, n is 2, 3, 4, or 5, and m is 0, 1, 2, or 3, provided that n+m is not more than 6, and provided that if Y is N completing a dihydroindole ring attached via the 1-position then m is 2 or 3; and if Y is NR<1> completing a dihydroindole ring linked via the 2-position then m is 1, 2, or 3; the dotted line, emanating from X, indicates an optional; when it does not indicate a bond, X is N, CH or CON; and when it indicates a bond, X is C; R<1> is hydrogen, acyl, thioacyl, C1-6 -alkoxycarbonyl, C1-6 -alkylaminocarbonyl, C1-6 -alkylthiocarbonyl, - C1-6 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, arylaminocarbonyl, heteroarylaminocarbonyl; R<2> -R<5> are independently selected from hydrogen, halogen, cyano, nitro, C1-6 -alkyl, C1-6 alkoxy, C1-6 -alkylcarbonyl, C1-6 -alkylcarbonylamino, C1-6 -alkylthio, trifluoromethyl; or two adjacent groups taken from R<2> -R<5> may be joined and designate a --(CH2)3 --, or --CH.dbd.CH--NH--, thereby forming a fused 5 membered ring; R<6> -R<9> and R<11> -R<12> are independently hydrogen, halogen, cyano, nitro, trifluoromethyl or C1-6 -alkylsulfonyl; or two adjacent groups taken from R<6> -R<9> may together form a methylenedioxy group; R<10> is as defined for R<1> above; or a pharmaceutically acceptable acid addition salt thereof. 2. A compound of claim 1, characterized in that Y is CH2. 3. A compound of claim 1, characterized in that Y is NR<1> or N completing a dihydroindole ring. 4. A compound of claim 3, characterized in that Y is NR<1> and that the resulting dihydroindole ring is linked to the (CH2)n --W--(CH2)m group via the 2- or 3-position. 5. A compound of claim 3, characterized in that Y is N and the resulting dihydroindole is linked to the (CH2)n --W--(CH2)m group via the 1-position. 6. A compound of claim 2, characterized in that A is a group a) linked to X via the 2 or the 3 position, or a group b). 7. A compound of claim 6, characterized in that A is a group a) linked to X via the 2 or the 3 position. 8. A compound of claim 2, characterized in that A is a group c) linked to X via the 4, 5, 6, or 7 position. 9. A compound of claims 3 to 5, characterized in that A is a group a) linked to X via the 2 or the 3 position, or a group b). 10. A compound of claim 9, characterized in that A is a group a) linked to X via the 2 or the 3 position. 11. A compound of claims 3 to 5, characterized in that A is a group c) linked to X via the 4, 5, 6, or 7 position. 12. A compound of claims 1 to 11, characterized in that X is CH. 13. A compound of claims 1 to 11, characterized in that X is C. 14. A compound of claims 1 to 11, characterized in that X is N. 15. A pharmaceutical composition characterized in that it comprises a compound of any of claims 1 to 14 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents. 16. Use of a compound of any of claims 1-14 for the manufacture of a medicament useful in treatment the positive and negative symptoms of schizophrenia, other psychoses, anxiety disorders, including generalized anxiety disorder, panic disorder and obsessive compulsive disorder, depression, alcohol abuse, impulse control disorders, aggression, side effects induced by conventional antipsychotic agents, ischaemic disease states, migraine, senile dementia and cardiovascular disorders and in the improvement of sleep. 17. A method of treatment the positive and negative symptoms of schizophrenia, other psychoses, anxiety disorders, including generalized anxiety disorder, panic disorder and obsessive compulsive disorder, depression, alcohol abuse, impulse control disorders, aggression, side effects induced by conventional antipsychotic agents, ischaemic disease states, migraine, senile dementia and cardiovascular disorders and in the improvement of sleep, comprising administration of a therapeutically acceptable amount of a compound according to any one of claims 1 to 14.